InSysBio to take part in ACoP 2026

2 1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

5 1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.

8 1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

12 1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.

17 1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.

22 1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website

30 1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

events

Conference

September 9, 2026

InSysBio announces its participation in 2026 American Conference on Pharmacometrics (ACoP 2026) which is to be held from October 11-14, 2026 at the Gaylord National Resort & Convention Center, Oxon Hill, Maryland, USA. InSysBio team is going to present its QSP modeling services & software to optimize drug development at the Booth #11 and 6 posters, namely:

Monday, October 12, 2026 7:00 AM - 5:00 PM EDT

(M-088) "Evaluating Combination Dosing Regimens of the Anti-BCMA Antibody-Drug Conjugate Belantamab Mafodotin and Monoclonal Antibody Belantamab in Relapsed or Refractory Multiple Myeloma Using QSP modeling" by Jingqi Q. X. Gong¹, Galina Lebedeva², Alexandra Diakonova², Geraldine Ferron-Brady¹, Oleg Demin², John D. Clements¹

Affiliations: (1) GSK, Upper Providence, PA, USA, (2) InSysBio

(M-089) "QSP Model of PSMAxCD3 T-cell Engagers Generates Cytokine-based CRS Risk and Efficacy-related Biomarker Predictions to Optimize Clinical Dosing Strategies" by Jingqi Q. X. Gong¹, Tatiana Karelina², Dmitry Shchelokov², Polina Maliukova², Olga Ivanova², Maria Myshkina², Oleg Demin Jr², John Clements¹, Stefan Zajic¹, Murad Melhem³

Affiliations: (1) GSK, Collegeville, PA, USA, (2) InSysBio, (3) GSK, Waltham, MA, USA

Tuesday, October 13, 2026 7:00 AM - 5:00 PM EDT

(T-038) "SBML-based genome-scale QSP modelling of asthma integrating CYTOCON DB, EHMN2026 with Neural ODEs" by Igor Goryanin^1,3, Oleg Demin², Irina Goryanin³

Affiliations: (1) University of Edinburgh, (2) InSysBio, (3) IQANOVA LTD

(T-048) "AI-assisted SBML-based QSP modelling of CAR-T therapy: automated model evolution, calibration, and combination therapy evaluation" by Igor Goryanin^1,3, Oleg Demin², Irina Goryanin³

Affiliations: (1) University of Edinburgh, (2) InSysBio, (3) IQANOVA LTD

(T-113) "Simplified tau pathology model for preclinical efficacy of PROTAC to investigate translation from in vitro protein degradation to in vivo efficacy" by Tatiana Karelina, Marina Morozova

Wednesday, October 14, 2026 7:00 AM - 1:30 PM EDT

(W-093) "Context-of-Use–Driven Validation of Machine Learning Surrogate Models for Accelerating Virtual Patient Workflows in a QSP Model of Erythropoiesis" by Anna Viktorenko¹, Alexander Stepanov¹, Igor Goryanin², Oleg Demin¹

Affiliations: (1) InSysBio, (2) University of Edinburgh

Check out our posters and Booth #11 at ACoP 2026!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

←	June 2020	→
Mo	Tu	We	Th	Fr	Sa	Su
1	2 1. 02 Jun 2020 13:24 InSysBio to announce the launch of QSP model of COVID-19 The new open source project to be developed and updated Online InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.	3	4	5 1. 05 Jun 2020 15:04 InSysBio to present IRT Navigator 3 InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.	6	7
8 1. 08 Jun 2020 15:30 InSysBio to perform the first step in development of COVID-19 QSP model InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.	9	10	11	12 1. 12 Jun 2020 16:45 InSysBio to release the new version of Cytocon DB 1.1.6.4 We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.	13	14
15	16	17 1. 17 Jun 2020 15:48 InSysBio to welcome its new team member Dr. Neil Benson InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development (Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.	18	19	20	21
22 1. 22 Jun 2020 17:04 InSysBio team posters to be presented at AACR Virtual Annual Meeting II AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website	23	24	25	26	27	28
29	30 1. 30 Jun 2020 15:45 InSysBio to present COVID-19 QSP model further development InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

Upcoming Events

11.10

InSysBio to take part in ACoP 2026